Last reviewed · How we verify
Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium
Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium is a Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently in Phase 3 development for Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.
This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways.
This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways. Used for Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.
At a glance
| Generic name | Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) |
| Target | Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate is an inhaled corticosteroid that suppresses airway inflammation and immune responses. Formoterol fumarate is a long-acting beta-2 agonist (LABA) that activates beta-2 receptors on airway smooth muscle to cause bronchodilation. Glycopyrronium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine-mediated bronchoconstriction. Together, these three agents provide anti-inflammatory, bronchodilatory, and anticholinergic effects for maintenance therapy in chronic obstructive pulmonary disease (COPD).
Approved indications
- Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nasopharyngitis
- Oral candidiasis
Key clinical trials
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (PHASE3)
- Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (PHASE2)
- Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting
- Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium CI brief — competitive landscape report
- Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI
Frequently asked questions about Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium
What is Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium?
How does Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium work?
What is Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium used for?
Who makes Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium?
What drug class is Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium in?
What development phase is Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium in?
What are the side effects of Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium?
What does Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium target?
Related
- Drug class: All Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) drugs
- Target: All drugs targeting Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
- Manufacturer: Chiesi Farmaceutici S.p.A. — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults
- Compare: Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium vs similar drugs
- Pricing: Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium cost, discount & access